AC Immune discovers next-generation antibodies focused on neurodegenerative diseases

24 August 2017

Swiss biotech AC Immune (Nasdaq: ACIU) shares gained 3.5% in response to the announcement that it has discovered two new antibodies using its proprietary SupraAntigen platform, against two targets in the pathogenesis of neurodegenerative diseases.

Alpha-synuclein is an established target for Parkinson's disease and other Lewy body diseases, while TDP-43 is a recently identified target of growing interest for neuro-orphan indications such as frontotemporal lobar degeneration. More interestingly, says the company, both targets also play an important role in other significant neurodegenerative indications such as Alzheimer's disease, beyond the established hallmarks of Abeta and Tau. These next-generation antibodies were discovered using the company's proprietary SupraAntigen platform, which has already generated four products in clinical development, including crenezumab partnered with Genentech/Roche (ROG: SIX) in Phase III for Alzheimer's.

Powerful combination of therapeutics and diagnostics

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK